Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

January 31, 2030

Conditions
MedulloblastomaEpendymoma
Interventions
DRUG

administration of axitinib in combination with etoposide

"1. st stage:~ * Axitinib (Inlyta®) PO, in the morning and in the evening every day~ * Level -1 : Dose 1.2 mg/m²~ * Level 1: Dose 1.6 mg/m²~ * Level 2: Dose 2.0 mg/m²~ * Level 3: Dose 2.4 mg /m² (equivalent to 4 mg in adults)~ * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m²/day in the evening orally every day fasting (capped to a maximum of 50 mg/day) First patient will be enrolled at dose level 1~2. nd stage:~ * Axitinib (Inlyta®) dosing as selected at the 1st stage~ * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m2/ day in the evening orally every day fasting(capped to a maximum of 50 mg/day)"

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER

NCT06485908 - Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma | Biotech Hunter | Biotech Hunter